These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

403 related items for PubMed ID: 33632314

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Diagnostic performance and prognostic value of preoperative 18F-FDG PET/CT in renal cell carcinoma patients with venous tumor thrombus.
    Chen S, Zhao Y, Tang Q, Wu C, Wang A, Ma L, Zhang X, Chen J, Gao Y, Liao X, Feng N, Fan Y, Zhang J, Li X, Liu M.
    Cancer Imaging; 2022 Nov 26; 22(1):65. PubMed ID: 36435856
    [Abstract] [Full Text] [Related]

  • 6. The role of dual tracer PSMA and FDG PET/CT in renal cell carcinoma (RCC) compared to conventional imaging: A multi-institutional case series with intra-individual comparison.
    Tariq A, Kwok M, Pearce A, Rhee H, Kyle S, Marsh P, Raveenthiran S, Wong D, McBean R, Westera J, Dunglison N, Esler R, Navaratnam A, Yaxley JW, Thomas P, Pattison DA, Roberts MJ.
    Urol Oncol; 2022 Feb 26; 40(2):66.e1-66.e9. PubMed ID: 34895817
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Diagnostic performance of 11C-choline PET/CT and FDG PET/CT for staging and restaging of renal cell cancer.
    Nakanishi Y, Kitajima K, Yamada Y, Hashimoto T, Suzuki T, Go S, Kanematsu A, Nojima M, Yamakado K, Yamamoto S.
    Ann Nucl Med; 2018 Dec 26; 32(10):658-668. PubMed ID: 30120698
    [Abstract] [Full Text] [Related]

  • 10. Imaging of renal cell carcinoma in patients with acquired cystic disease of the kidney: comparison 11C-choline and FDG PET/CT with dynamic contrast-enhanced CT.
    Kitajima K, Yamamoto S, Kawanaka Y, Katsuura T, Fujita M, Nakanishi Y, Yamada Y, Hashimoto T, Suzuki T, Go S, Kanematsu A, Nojima M, Yamakado K.
    Jpn J Radiol; 2019 Feb 26; 37(2):165-177. PubMed ID: 30377936
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Semi-quantitative F-18-FDG PET/computed tomography parameters for prediction of grade in patients with renal cell carcinoma and the incremental value of diuretics.
    Singh H, Arora G, Nayak B, Sharma A, Singh G, Kumari K, Jana S, Patel C, Pandey AK, Seth A, Kumar R.
    Nucl Med Commun; 2020 May 26; 41(5):485-493. PubMed ID: 32168262
    [Abstract] [Full Text] [Related]

  • 13. Restaging [18F] fludeoxyglucose positron emission tomography/computed tomography scan in recurrent cutaneous squamous cell carcinoma: Diagnostic performance and prognostic significance.
    Mahajan S, Barker CA, Mauguen A, Singh B, Pandit-Taskar N.
    J Am Acad Dermatol; 2020 Apr 26; 82(4):878-886. PubMed ID: 31562942
    [Abstract] [Full Text] [Related]

  • 14. Efficacy of 18F-Fluorodeoxyglucose positron emission tomography/computed tomography for detecting renal cell carcinoma in patients with end-stage renal disease.
    Hirasawa H, Taketomi-Takahashi A, Katsumata N, Higuchi T, Sekine Y, Suzuki K, Kaneko Y, Hiromura K, Fukushima Y, Tsushima Y.
    Jpn J Radiol; 2024 Oct 26; 42(10):1178-1186. PubMed ID: 38795287
    [Abstract] [Full Text] [Related]

  • 15. Clinical role of early dynamic FDG-PET/CT for the evaluation of renal cell carcinoma.
    Nakajima R, Abe K, Kondo T, Tanabe K, Sakai S.
    Eur Radiol; 2016 Jun 26; 26(6):1852-62. PubMed ID: 26403580
    [Abstract] [Full Text] [Related]

  • 16. Restaging clear cell renal carcinoma with 18F-FDG PET/CT.
    Fuccio C, Ceci F, Castellucci P, Spinapolice EG, Palumbo R, D'Ambrosio D, Bernardo A, Brunocilla E, Schiavina R, Maffione AM, Chondrogiannis S, Grassetto G, Colletti PM, Rubello D, Fanti S, Trifirò G.
    Clin Nucl Med; 2014 Jun 26; 39(6):e320-4. PubMed ID: 24566409
    [Abstract] [Full Text] [Related]

  • 17. Role of Positron Emission Tomography Imaging in Metabolically Active Renal Cell Carcinoma.
    Karivedu V, Jain AL, Eluvathingal TJ, Sidana A.
    Curr Urol Rep; 2019 Aug 29; 20(10):56. PubMed ID: 31468240
    [Abstract] [Full Text] [Related]

  • 18. Impact of maximum standardized uptake value (SUVmax) evaluated by 18-Fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography (18F-FDG-PET/CT) on survival for patients with advanced renal cell carcinoma: a preliminary report.
    Namura K, Minamimoto R, Yao M, Makiyama K, Murakami T, Sano F, Hayashi N, Tateishi U, Ishigaki H, Kishida T, Miura T, Kobayashi K, Noguchi S, Inoue T, Kubota Y, Nakaigawa N.
    BMC Cancer; 2010 Dec 03; 10():667. PubMed ID: 21129184
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. 18F-FDG and 68GA-Prostate-Specific Membrane Antigen PET/CT Perform Better Than CT Alone in Restaging Papillary Renal Cell Carcinoma Recurrence.
    Gasparro D, Scarlattei M, Manuguerra R, Guglielmo P, Migliari S, Sammartano A, Baldari G, Maestroni U, Silini EM, Ruffini L.
    Clin Nucl Med; 2021 Sep 01; 46(9):e458-e460. PubMed ID: 34374683
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.